Format

Send to

Choose Destination
Int J Urol. 2016 Aug;23(8):646-53. doi: 10.1111/iju.13134. Epub 2016 Jun 3.

Androgen receptor splice variant 7 in castration-resistant prostate cancer: Clinical considerations.

Author information

1
Division of Hematology and Medical Oncology, Mayo Clinic, Scottsdale, Arizona, USA.
2
Departments of Oncology and Urology, Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland, USA.

Abstract

Constitutively-active ligand-independent splice variants of the androgen receptor are an adaptive response by prostate cancer cells to escape androgen deprivation therapy and novel androgen receptor-directed treatments. Androgen receptor splice variant 7 is the most common splice variant detected in clinical biospecimens, and emerging data now suggest that the presence of tumoral androgen receptor splice variant 7 might be indicative of primary and acquired resistance to next-generation androgen pathway inhibitors, such as abiraterone and enzalutamide. At the same time, taxane chemotherapy might retain its efficacy regardless of androgen receptor splice variant 7 status, thus suggesting the potential for a predictive biomarker guiding treatment selection in men with metastatic castration-resistant prostate cancer. Herein, we review the preclinical data elucidating the structure and function of androgen receptor splice variant 7, we describe the existing clinical data using this biomarker in metastatic castration-resistant prostate cancer, and we highlight potential therapeutic strategies to target androgen receptor splice variant 7-expressing prostate cancer.

KEYWORDS:

androgen; androgen receptor splice variant 7; hormone therapy; prostate cancer; resistance

PMID:
27255944
DOI:
10.1111/iju.13134
[Indexed for MEDLINE]
Free full text

Supplemental Content

Full text links

Icon for Wiley
Loading ...
Support Center